Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations

PLoS One. 2012;7(9):e44660. doi: 10.1371/journal.pone.0044660. Epub 2012 Sep 4.

Abstract

Background: Induced pluripotent stem cells (iPSC) provide means to study the pathophysiology of genetic disorders. Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a malignant inherited ion channel disorder predominantly caused by mutations in the cardiac ryanodine receptor (RyR2). In this study the cellular characteristics of CPVT are investigated and whether the electrophysiological features of this mutation can be mimicked using iPSC -derived cardiomyocytes (CM).

Methodology/principal findings: Spontaneously beating CMs were differentiated from iPSCs derived from a CPVT patient carrying a P2328S mutation in RyR2 and from two healthy controls. Calcium (Ca(2+)) cycling and electrophysiological properties were studied by Ca(2+) imaging and patch-clamp techniques. Monophasic action potential (MAP) recordings and 24h-ECGs of CPVT-P2328S patients were analyzed for the presence of afterdepolarizations. We found defects in Ca(2+) cycling and electrophysiology in CPVT CMs, reflecting the cardiac phenotype observed in the patients. Catecholaminergic stress led to abnormal Ca(2+) signaling and induced arrhythmias in CPVT CMs. CPVT CMs also displayed reduced sarcoplasmic reticulum (SR) Ca(2+) content, indicating leakage of Ca(2+) from the SR. Patch-clamp recordings of CPVT CMs revealed both delayed afterdepolarizations (DADs) during spontaneous beating and in response to adrenaline and also early afterdepolarizations (EADs) during spontaneous beating, recapitulating the changes seen in MAP and 24h-ECG recordings of patients carrying the same mutation.

Conclusions/significance: This cell model shows aberrant Ca(2+) cycling characteristic of CPVT and in addition to DADs it displays EADs. This cell model for CPVT provides a platform to study basic pathology, to screen drugs, and to optimize drug therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Action Potentials / drug effects
  • Adult
  • Animals
  • Calcium / metabolism*
  • Calcium Signaling / drug effects
  • Cell Differentiation
  • Cells, Cultured
  • Epinephrine / pharmacology
  • Humans
  • Induced Pluripotent Stem Cells / drug effects
  • Induced Pluripotent Stem Cells / metabolism*
  • Induced Pluripotent Stem Cells / pathology
  • Ion Transport / drug effects
  • Male
  • Mice
  • Mice, Nude
  • Models, Cardiovascular
  • Mutation
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / metabolism*
  • Myocytes, Cardiac / pathology
  • Patch-Clamp Techniques
  • Ryanodine Receptor Calcium Release Channel / genetics
  • Ryanodine Receptor Calcium Release Channel / metabolism*
  • Sarcoplasmic Reticulum / drug effects
  • Sarcoplasmic Reticulum / metabolism
  • Tachycardia, Ventricular / genetics
  • Tachycardia, Ventricular / metabolism*
  • Tachycardia, Ventricular / pathology

Substances

  • Ryanodine Receptor Calcium Release Channel
  • Calcium
  • Epinephrine

Supplementary concepts

  • Polymorphic catecholergic ventricular tachycardia

Grants and funding

This work was supported by Academy of Finland (http://www.aka.fi/en-GB/A/), TEKES (http://www.tekes.fi/en/), Finnish Foundation for Cardiovascular Research (http://www.sydantutkimussaatio.fi), Pirkanmaa Hospital District (www.pshp.fi), Ida Montin Foundation (http://www.idamontininsaatio.fi), Finnish Medical Foundation/The Finnish Medical Society Duodecim (www.duodecim.fi/), Aarne Koskelo Foundation (www.aarnekoskelonsaatio.fi/), Orion-Farmos Research Foundation (http://www.orion.fi/Tutkimus-ja-tuotekehitys/Orion-Farmos-Tutkimussaatio/), Finnish Cultural Foundation (www.skr.fi/), and Oskar Öflund Foundation (www.oskaroflund.fi/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.